Adam Lee

8PUBLICATIONS
40CO-AUTHORS
Memory and attentionOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 10, 2026
Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

|Mar 27, 2026
Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe.

Winson Y Cheung, Adam Lee, Helena Bote de Cabo

|Feb 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Arnaud Scherpereel, Paul Baas, Anna K Nowak

|Feb 13, 2026
Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.

Angelo Delmonte, Nicola Gentili, Andrea Roncadori

|Nov 12, 2025
A Bayesian Model Leveraging Multiple External Data Sources to Improve the Reliability of Lifetime Survival Extrapolations in Metastatic Non-Small-Cell Lung Cancer.

Daniel J Sharpe, Georgia Yates, Mohammad Ashraf Chaudhary

|Mar 13, 2025
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC.

Jürgen Wolf, Sarah Goring, Adam Lee

Pageof 2

Frequent Collaborators

2 joint publications

Anna K Nowak

2 joint publications

Dariusz Kowalski

2 joint publications

Aaron S Mansfield

2 joint publications

Anne S Tsao